ArtVentive Medical Group, Inc. (OTC Bulletin Board: AVTD) announced the Company has signed a manufacturing, research and development agreement with Medical Murray Inc. (ISO certified and FDA registered). Medical Murray is a leader in medical device and product development including specialty manufacturing services.

The agreement is projected to significantly reduce ArtVentive's development time to deliver products for clinical studies and commercialization. The first Endoluminal Occlusion Device (EOS) prototypes were produced prior to entering into the Agreement with Medical Murray to demonstrate the device's dimensional properties and functionality. The new series of functional prototypes comprise of a combination of an implant scaffold with a polymeric cover and a delivery catheter that has been under development for the upcoming series of animal studies.

?This arrangement will significantly enhance our ability to bring products to markets swiftly while maintaining tight controls on manufacturing, research and development? said Jim Graham, President, ArtVentive Medical Group, Inc, ?We are pleased to have signed an agreement with such a world class organization.?

About ArtVentive Medical Group, Inc.

ArtVentive Medical Group, Inc., with corporate headquarters in San Marcos, California, is an innovative, multi-faceted medical device corporation focused on developing, manufacturing and marketing a family of endoluminal occlusion devices (EOS).

ArtVentive Medical Group, Inc., through its proprietary technology has developed unique minimally invasive occlusion devices and procedures bringing the current interventional image guided techniques to a new level of sophistication, resolving significant and unaddressed health issues. The EOS is a catheter based self-expandable device, serving for permanent or temporary (reversible) occlusion of body lumens. The patented revolutionary device will serve in many cases as a safe and reliable alternative to major surgery. ArtVentive's EOS device targets a substantive market demand in several major clinical areas, including women's health, peripheral and neurological vascular disorders, and interventional cardiology procedures.

More information about the company can be found at www.artventivemedical.com.

Forward-Looking Statements

This news release may include "forward-looking statements," within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. These statements are based on the beliefs by our management as well as assumptions made by and information currently available to the company. These statements reflect the company's current views with respect to future events and are not guarantees of future performance. These statements may involve risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the said forward-looking statements. These factors include, among other things, the company's periodic reports filed with the Securities and Exchange Commission. You should not put undue reliance on any forward-looking statements. Except as required by law, the company does not undertake any obligation to update or revise these forward-looking statements to reflect new information or events or circumstances that occur after the date of this news release or to reflect the occurrence of unanticipated events or otherwise. Readers are advised to review the company's filings with the Securities and Exchange Commission which are available from the SEC's EDGAR database at www.sec.gov, at various SEC reference facilities in the United States.

ArtVentive Medical Group, Inc.
H.J. (Jim) Graham, President
760-471-7700
hjgraham@artventivemedical.com